Accueil > TERI Department > Gastroenterology and technologies for health
Gastroenterology and technologies for health
Objectives
Our team aims at understanding and treating human digestive cancers. Our work is organized around two main axes:
- The first, which is very fundamental, focuses on the origin of rare neuroendocrine tumors of the small intestine, and tries to decipher why some patients exhibit hundreds of independent tumors.
- The second aims at developing new, innovative anti-cancer molecules and transfer them to the clinic.
Projects
Digestive cancers represent a major public health problem. Our team seeks to unravel the mechanisms of their invasion and to cure them, through two lines of research.
1) Under normal conditions, enteroendocrine cells sense the contents of the intestine and release hormones to regulate gastrointestinal activity, food intake and systemic metabolism. Numerous cell subtypes that spatio-temporally regulate digestion throughout the gut have been described.
However, little is known about these cells during the formation of small intestinal neuroendocrine tumors (NETs), which have so far been considered and treated as a single pathology. Our team’s project therefore aims at understanding the formation of these neuroendocrine tumors and the development of new associated therapies.
2) The second axis of study is based on the use of a promising technology called radioimmunotherapy, already used to treat NETs in clinical settings. This project is based on an industrial chair awarded by ANR and Orano. We have recently characterized cell surface proteins that are highly specific to cancer cells, making them prime targets for therapy. Four of them, at different stages of development in terms of type of pathology, presence of a vector (antibody, peptide), etc., have been chosen for their biological properties. The ambitious challenge we have set ourselves is to address various innovative metals to tumor cells in order to destroy them. The ultimate goal is to find the best target/carrier/radiation emitter combination, in order to select one or more radiopharmaceuticals compatible with rapid clinical development in humans.
-
Benjamin Gibert
CRCN CNRS
benjamin.gibert@lyon.unicancer.frThomas Walter
PU-PH
thomas.walter@chu-lyon.fr
Team members
Publications
-
Systematic resection of the visible scar, after incomplete endoscopic resection of rectal neuroendocrine tumours
Cheminel L, Lupu A, Wallenhorst T, Lepilliez V, Leblanc S, Albouys J, Ali EA, Barret M, Lorenzo D, De Mestier L, Burtin P, Girot P, Le Baleur Y, Gerard R, Yzet C, Tchirikhtchian K, Degand T, Culetto A, Lemmers A, Schaefer M, Chevaux JB, Zhong P, Hervieu V, Subtil F, Rivory J, Fine C, Jacques J, Walter T, Pioche M Am J Gastroenterol
Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN NetworkAl Mansour L, De Mestier L, Haissaguerre M, Afchain P, Hadoux J, Lecomte T, Morland D, Cottereau AS, De Rycke O, Tlili G, Tordo J, Janier M, Deville A, Walter T J Nucl Med
Strategies for the Nuclear Delivery of Metal Complexes to Cancer CellsHuynh M, Vinck R, Gibert B, Gasser G Advanced Materials
-
Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor
Ducarouge B, Redavid AR, Victoor C, Fonseca A, Hervieu M, Bergé R, Lengrand J, Vieugué P, Neves D, Goddard I, Richaud M, Laval PA, Rama N, Goldschneider D, Paradisi A, Gourdin N, Chabaud S, Treilleux I, Gadot N, Ray-Coquart I, Decaudin D, Némati F, Marangoni E, Mery-Lamarche E, Génestie C, Tabone-Eglinger S, Devouassoux M, Moore KJ, Gibert B*, Mehlen P* and Bernet A*. co-last authors Cell Death and Differentiation
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma: the PRODIGE 41-BEVANEC randomised phase II studyWalter T, Lièvre A, Coriat A, Malka D, Elhajbi F, Di Fiore F, Hentic O, Smith D, Hautefeuille V, Roquin G, Perrier M, Dahan L, Granger V, Sobhani I, Mineur L, Niccoli P, Assenat E, Scoazec JY, Le Malicot K, Lepage C, Lombard-Bohas C Lancet Oncol.
From netrin-1-targeted SPECT/CT to internal radiotherapy for management of advanced solid tumorsDavid Kryza D*, Wischhusen J*, Richaud M*, Hervieu M, Sidi Boumedine J, Delcros JG, Besse S, Baudier T, Laval PA, Breusa S, Boutault E, Clermidy H, Rama N, Ducarouge B, Chezal JM, Giraudet AL, Walter T, Mehlen P, Sarrut D and Gibert B EMBO Molecular Medicine
-
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study
Lepage C, Phelip JM, Lievre A, Le-Malicot K, Dahan L, Tougeron D, Toumpanakis C, Di-Fiore F, Lombard-Bohas C, Borbath I, Coriat R, Lecomte T, Guimbaud R, Petorin C, Legoux JL, Michel P, Scoazec JY, Smith D, Walter T Eur J Cancer
Hepatic inflammation elicits production of proinflammatory netrin-1 through exclusive activation of translationBarnault R, Verzeroli C, Fournier C, Michelet M, Redavid AR, Chicherova I, Plissonnier ML, Adrait A, Khomich O, Chapus F, Richaud M, Hervieu M, Reiterer V, Centonze FG, Lucifora J, Bartosch B, Rivoire M, Farhan H, Couté Y, Mirakaj V, Decaens T, Mehlen P, Gibert B, Zoulim F, Parent R. Hepatology
The comparative roadmaps of reprogramming and transformation unveiled that cellular plasticity is broadly controlled by a c-Myc/Atoh8/Sfrp1 axisHuyghe A, Furlan G, Schroeder J, Cascales E, Trajkova A, Ruel M, F. Stüder, F. Mugnier, De Matteo L, J. Wang J, Yu Y, N. Rama N, Gibert, B, Kielbassa J, Tonon L, Wajda P, Gadot N, Brevet M, Siouda M, Mulligan P, Dante R, Liu P, Gronemeyer H, Mendoza-Parra M, Polo J and F. Lavial F Nature Cell Biol
-
Targeting netrin-3 in Small Cell Lung Cancer and Neuroblastoma
Jiang S, Richaud M, Vieugué P, Rama N, Delcros JG, Siouda M, Sanada M, Redavid AR, Ducarouge B, Hervieu M, Breusa S, Manceau A, Gattolliat CH, Gadot N, Combaret V, Neves D, Ortiz-Cuaran S, Saintigny P, Meurette O, Walter T, Janoueix-Lerosey I, Hofman P, Mulligan P, Goldshneider G, Mehlen P and Gibert B. EMBO Mol Med
Niche derived netrin-1 regulates hematopoietic stem cell dormancy via its receptor neogenin-1Renders S, Svendsen AF, Panten J, Rama N, Maryanovich M, Sommerkamp P, Ladel L, Redavid AR, Gibert B, Lazare S, Ducarouge B, Schönberger K, Narr A, Tourbez M, Dethmers-Ausema B, Zwart E, Hotz-Wagenblatt A, Zhang D, Korn C, Zeisberger P, Przybylla A, Sohn M, Mendez-Ferrer S, Heikenwälder M, Brune M, Klimmeck D, Bystrykh L, Frenette PS, Mehlen P, de Haan G, Cabezas-Wallscheid N, Trumpp A Nature Communications
-
Failed Apoptosis Enhances Melanoma Cancer Cell Aggressiveness
Berthenet K, Castillo Ferrer C, Fanfone D, Popgeorgiev N, Neves D, Bertolino P, Gibert B, Hernandez-Vargas H, Ichim G. Cell Rep
CDYL2 Epigenetically Regulates MIR124 to Control NF-κB/STAT3-Dependent Breast Cancer Cell PlasticitySiouda M, Dujardin AD, Barbollat-Boutrand L, Mendoza-Parra MA, Gibert B, Ouzounova M, Bouaoud J, Tonon L, Robert M, Foy JP, Lavergne V, Manie SN, Viari A, Puisieux A, Ichim G, Gronemeyer H, Saintigny P, Mulligan P. iScience
-
Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study.
Walter T, Lepage C, Coriat R, Barbier E, Cadiot G, Caroli-Bosc FX, Aparicio T, Bouhier-Leporrier K, Hentic-Dhome O, Gay F, Dupont-Gossart AC, Duluc M, Lepere C, Lecomte T, Smith D, Petorin C, Di-Fiore F, Ghiringhelli F, Legoux JL, Guimbaud R, Baudin E, Lombard-Bohas C, de Baère T Eur J Cancer
Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors: A National Study from the French Group of Endocrine Tumors (GTE)Rault-Petit B, Do Cao C, Guyétant S, Guimbaud R, Rohmer V, Julié C, Baudin E, Goichot B, Coriat R, Tabarin A, Ramos J, Goudet P, Hervieu V, Scoazec JY, Walter T Ann Surg
Neuropilin-2 contributes to tumor progression in preclinical models of small intestinal neuroendocrine tumorsBollard J, Patte C, Radkova K, Massoma P, Chardon L, Valantin J, Gadot N, Goddard I, Vercherat C, Hervieu V, Gouysse G, Scoazec JY, Walter T, Roche C J Pathol
Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid TumorsRobelin P, Hadoux J, Forestier J, Planchard D, Hervieu V, Berdelou A, Scoazec JY, Valette PJ, Leboulleux S, Ducreux M, Lombard-Bohas C, Baudin E, Walter T J Thorac Oncol
-
Ultrasound molecular imaging as a non-invasive companion diagnostic for 1 netrin-1 interference therapy in breast cancer
Wischhusen J, Wilson KE, Delcros JG, Molina-Peña R, Gibert B, Jiang S, Ngo J, Goldschneider D, Mehlen P, Willmann J, Padilla F. Theranostics
-
p53-dependent programmed necrosis controls germ cell homeostasis during spermatogenesis
Napoletano F, Gibert B, Yacobi-Sharon K, Vincent S, Favrot C, Mehlen P, Girard V, Teil M, Chatelain G, Walter L, Arama E, Mollereau B PLoS Genetics
Maintaining quality of life for patients with neuroendocrine tumours.Walter T Lancet Oncol
Non-canonical NOTCH3 signalling limits tumour angiogenesisLin S, Negulescu A, Bulusu S, Gibert B, Delcros JG, Ducarouge B, Rama N, Gadot N, Treilleux I, Saintigny P, Meurette O, Mehlen P Nature Communications
Desmoid Tumors and Celecoxib with SorafenibBenech N, Walter T, Saurin JC N Engl J Med
Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine CarcinomasLamarca A, Walter T, Pavel M, Borbath I, Freis P, Nuñez B, Childs A, McNamara MG, Hubner RA, Garcia-Carbonero R, Meyer T, Valle JW, Barriuso J J Natl Cancer Inst
-
Structural decoding of netrin-4 reveals a regulatory function towards mature basement membranes
Reuten R, Patel TR, McDougall M, Rama N, Nikodemus D, Gibert B, Delcros JG, Prein C, Meier M, Metzger S, Zhou Z, Kaltenberg J, McKee KK, Bald T, Tüting T, Zigrino P, Djonov V, Bloch W, Clausen-Schaumann H, Poschl E, Yurchenco PD, Ehrbar M, Mehlen P, Stetefeld J, Koch M Nature Communications
Everolimus in ileum neuroendocrine tumoursWalter T, Lombard-Bohas C The Lancet